Last reviewed · How we verify
Once daily immunosuppression regimen
A once-daily immunosuppressive regimen that reduces the frequency of drug administration while maintaining therapeutic immunosuppression, likely through combination or sustained-release formulation of established immunosuppressive agents.
A once-daily immunosuppressive regimen that reduces immune system activity to prevent organ rejection or manage autoimmune conditions. Used for Organ transplant rejection prevention, Autoimmune disease management.
At a glance
| Generic name | Once daily immunosuppression regimen |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Immunosuppressive regimen |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This represents a dosing innovation rather than a novel molecular mechanism, designed to improve patient adherence and convenience in transplant or autoimmune disease management. The regimen typically combines or reformulates existing immunosuppressive drugs (such as calcineurin inhibitors, antiproliferatives, or corticosteroids) to achieve once-daily dosing while maintaining adequate drug exposure and efficacy.
Approved indications
- Organ transplant rejection prevention
- Autoimmune disease management
Common side effects
- Infection
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Bone marrow suppression
Key clinical trials
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (PHASE1, PHASE2)
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (PHASE3)
- Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® (PHASE2)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis (PHASE2)
- Once Daily Immunosuppression Regimen (PHASE4)
- Liver Transplantation With Tregs at MGH (PHASE1, PHASE2)
- Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: